NovoBliss Research Pvt Ltd
Gandhinagar, Gujarat, India
NCT Number: NCT05613660
A proof of science clinical study with randomized, four-arm, comparative, single-blind, within the arm - Dose-Response Study to evaluate the safety and efficacy of different collagen peptide-containing test treatments in adult human subjects.
The dose-response will be evaluated for the effectiveness of each test treatment in three different dosages that is 2.5 g Versus 5 g Versus 10 g.
22 subjects will be enrolled per dose per test treatment to complete 20 subjects per dose per test treatment.
Looking for future studies?
Notify Me30 year–50 year
All sexes
Interventional
Not applicable
Gandhinagar, Gujarat, India
A proof of science clinical study with randomized, four-arm, comparative, single-blind, within the arm - Dose-Response Study to evaluate the safety and efficacy of different collagen peptide-containing test treatments in adult human subjects.
The dose response will be evaluated for the effectiveness of each test treatment in three different dosages that is 2.5 g Versus 5 g Versus 10 g.
22 subjects will be enrolled per dose per test treatment to complete 20 subjects per dose per test treatment.
There are four different test treatments as mentioned below will be tested during study.
Considering proof of science study, a sufficient number of adult subjects with an age group of 30 - 50 years old (i) having mild to moderate crows' feet wrinkles near to eye area and (ii) mild to moderate joints pain, swelling, stiffness and decreased range of motion (iii) having complaints of hair fall, decreased hair growth, brittle nails will be recruited/enrolled.
In Bovine Arm, out of 66 subjects, a few subjects with osteoarthritis patients having present complaints of pain and stiffness in joints will be enrolled.
The collagen peptides effects of all 4 variants will be evaluated in enrolled subjects with mild to moderate acne.
The potential subjects will be screened as per the inclusion & exclusion criteria only after obtaining written informed consent from the subjects. The subjects will be instructed to visit the facility as per the below visits.
Subjects will be pre-screened by the screening department of NovoBliss Research. Subjects will be telephonically contacted by recruiting department prior to the enrolment visit. Subjects will be instructed during screening (prior to enrolment) not to wear any facial makeup during study visits to the facility. The study will be conducted in four different groups considering four different arms of test treatments.
Assessment of safety and efficacy parameters will be done before test treatment usage on Day 1, and will be compared with after test treatments usage on Day 10 (+2 Days), Day 30 (+2 Days), and Day 60 (+2 Days) within treatments and between treatments, between three dosages as listed-below.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The subject must fulfil all of the following inclusion criteria to be eligible for participation in the study unless otherwise specified.
Exclusion criteria
Subjects must not be enrolled in the study if they meet any one of the following criteria:
Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
Other names: VEGCOL™️
Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
Other names: PROCOL
Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
Other names: AQUACOL
Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
Other names: CALCOL
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in the facial wrinkles and fine lines of Crow's feet area, skin texture - roughness, dryness, wrinkles, smoothness using Visioscan® VC 20 Plus after 8 weeks of treatment, between treatments, between three different dosages and within a treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments in skin elasticity using DermaLab®Combo or equivalent (Right cheek) after 8 weeks of treatment, between treatments, between three different dosages, and within a treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments in skin hydration using MoitureMeterEPiD (Right cheek) after 8 weeks of treatment, between treatments, between three different dosages, and within a treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in Hair Thickness and Density in using CASLiteNova through Phototrichogram after 8 weeks of treatment, between treatments, between three different dosages, and within a treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in hair fall using a 60-second hair count (Hair Combing Method) after 8 weeks of treatment, between treatments, between three different dosages, and within a treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in body weight in Kg and Body Mass Index (BMI) Kg/m2 after 8 weeks of treatment, between treatments, between three different dosages, and within a treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in Joints Pain using VAS (0-10 cm) scoring evaluated by trained study staff after 8 weeks of treatment, between treatments, between three different dosages, and within a treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in muscle strength as assessed by the sum of the handgrip, elbow flexion, and extension, and knee flexion and extension strength evaluated by trained study staff after 8 weeks of treatment, between treatments, between three different dosages, and within a treatment
Time frame: Baseline visit i.e. during Visit 01 (04 days before Day 01) and Visit 02 (Day01) before application to Visit 05 (Day 57) and Visit 06 (Day 60)
Hair growth rate (µm/day) will be measured by using data of hair growth from Visit 01 and Visit 02 for baseline reading and from Visit 05 and Visit 06 for post-treatment reading.
Note: Hair growth rate (μm/day) will be measured by using data of hair growth from Visit 01 and Visit 02 for baseline reading and from Visit 05 and Visit 06 for post-treatment reading
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in Physician Global Assessment (PGA) scoring using the Griffiths scale - Skin dryness, redness, fine wrinkling/lines, coarse wrinkling/lines, laxity, roughness and sallowness after 8 weeks of treatment, between treatments, between three different dosages and within the treatment evaluated by dermatologist trained scorer
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in Glogau Skin Age after 8 weeks of treatment, between treatments, between three different dosages and within the treatment evaluated by a dermatologist trained scorer
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in scalp hair strength using the pull test method evaluated by dermatologist-trained scorer after 8 weeks of treatment, between treatments, between three different dosages, and within the treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in Physician Global Assessment (PGA) score for assessment of the signs of brittle nails, surface roughness, raggedness, and peeling evaluated by dermatologist-trained scorer after 8 weeks of treatment, between treatments, between three different dosages, and within the treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in Sleep Quality using Leeds Sleep Evaluation Questionnaires (LSEQ) evaluated by trained staff after 8 weeks of treatment, between treatments, between three different dosages, and within the treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for the requirement of consumption of rescue medications for Joints pain during and after 8 weeks of treatment, between treatments, between three different dosages, and within the treatment
Time frame: Baseline (Day01) to Day 10 (+2Days), Day 30 (+2Days) and Day 60 (+2Days)
To evaluate the effectiveness of the test treatments perception and consumer feedback on skin elasticity, suppleness, deep and sound sleep, digestion and gut health, joint health, and nail and hair health using hedonic questionnaires evaluated by trained study staff after 8 weeks of treatment, between treatments, between three different dosages, and within the treatment
Time frame: Baseline (Day01) to Day 60 (+2Days)
To evaluate the effectiveness of the test treatments for change in PGA score of acne severity evaluated by dermatologist trained scorer in enrolled subjects with mild to moderate acne - between treatments, between three different dosages, and within the treatment
Time frame: Baseline (Day01) to Day 60 (+2Days)
To evaluate the effectiveness of the test treatments after 8 weeks of treatment in Anagen Telogen (A:T) ratio using pluck test - between treatments, between three different dosages and within treatment evaluated by dermatologist trained scorer to assess Hair growth cycle (Trichogram)
Time frame: Baseline (Day01) to Day 60 (+2Days)
Change in facial photographs (left/center/right) and nails photographs of the subjects in three different dosages and between treatments will be presented at the end of the study
NovoBliss Research Pvt Ltd
Other
A Proof of Science Clinical Study With Randomized, Four Arm, Comparative, Single-Blind, Within the Arm - Dose-Response Study to Evaluate the Safety, Efficacy of Different Collagen Peptide Containing Test Treatments in Adult Human Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06420804
Acne Vulgaris, Acneiform Eruptions
Pleasant Hill, California, United States
View Trial DetailsNCT01257555
Mild to Moderate Acne
Hayward, California, United States
View Trial DetailsNCT06263270
Arthralgia, Arthritis
Sunshine Coast, Birtinya QLD, Australia
View Trial DetailsNCT04497129
Arthralgia, Arthritis
Gilbert, Arizona, United States
View Trial Details